MA30991B1 - Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 - Google Patents

Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Info

Publication number
MA30991B1
MA30991B1 MA31990A MA31990A MA30991B1 MA 30991 B1 MA30991 B1 MA 30991B1 MA 31990 A MA31990 A MA 31990A MA 31990 A MA31990 A MA 31990A MA 30991 B1 MA30991 B1 MA 30991B1
Authority
MA
Morocco
Prior art keywords
agonists
receptors
benzamide derivatives
compounds
benzamide
Prior art date
Application number
MA31990A
Other languages
English (en)
Inventor
Alessandra Gaiba
Mark Patrick Healy
Christopher Norbert Johnson
Susan Roomans
Steven James Stanway
Martin Edward Swarbrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625098A external-priority patent/GB0625098D0/en
Priority claimed from GB0715145A external-priority patent/GB0715145D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30991B1 publication Critical patent/MA30991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

CETTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU SON DÉRIVÉ PHARMACEUTIQUEMENT ACCEPTABLE, OÙ R1, R2, R3, R4, R5, M, N ET X SONT TELS QUE DÉFINIS DANS LE MÉMOIRE. L'INVENTION DÉCRIT ÉGALEMENT UN PROCÉDÉ PERMETTANT DE PRÉPARER DE TELS COMPOSÉS, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT CES COMPOSÉS, AINSI QUE L'UTILISATION PHARMACOLOGIQUE DE CES COMPOSÉS.
MA31990A 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 MA30991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625098A GB0625098D0 (en) 2006-12-15 2006-12-15 Novel compounds
GB0715145A GB0715145D0 (en) 2007-08-03 2007-08-03 Novel compounds

Publications (1)

Publication Number Publication Date
MA30991B1 true MA30991B1 (fr) 2009-12-01

Family

ID=39149241

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31990A MA30991B1 (fr) 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Country Status (21)

Country Link
US (3) US20080167377A1 (fr)
EP (1) EP2101751A1 (fr)
JP (1) JP5069752B2 (fr)
KR (1) KR20090089868A (fr)
AR (1) AR064361A1 (fr)
AU (1) AU2007331471C1 (fr)
BR (1) BRPI0720254A2 (fr)
CA (1) CA2672631A1 (fr)
CL (1) CL2007003640A1 (fr)
CR (1) CR10849A (fr)
DO (1) DOP2009000124A (fr)
EA (1) EA015931B1 (fr)
IL (1) IL198931A0 (fr)
MA (1) MA30991B1 (fr)
MX (1) MX2009006474A (fr)
NO (1) NO20092314L (fr)
NZ (1) NZ577109A (fr)
PE (1) PE20081579A1 (fr)
SG (1) SG177203A1 (fr)
TW (1) TW200848014A (fr)
WO (1) WO2008071736A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172447A4 (fr) * 2007-07-03 2011-08-24 Astellas Pharma Inc Composé amide
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
WO2009085177A1 (fr) * 2007-12-19 2009-07-09 Amgen Inc. Dérivés de l'acide phénylacétique utiles comme modulateurs de l'inflammation
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
GB0810313D0 (en) * 2008-06-05 2008-07-09 Glaxo Group Ltd Novel compounds
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
ES2512727T3 (es) * 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
CN102596921B (zh) * 2009-09-29 2015-04-29 葛兰素集团有限公司 新化合物
EP2488168A1 (fr) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Traitement par polythérapie pour infections virales
NZ607306A (en) * 2010-07-30 2015-03-27 Allergan Inc Compounds and methods for skin repair
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
PE20131343A1 (es) 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
EP2814527A1 (fr) * 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2765128A1 (fr) * 2013-02-07 2014-08-13 Almirall, S.A. Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4
EP3030252B1 (fr) 2013-08-09 2018-11-07 Ardelyx, Inc. Composés et procédés d'inhibition du transport de phosphate
CA2997746A1 (fr) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Ted formes cristallines de grapiprant
AR103992A1 (es) 2015-01-16 2017-06-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Método para preparar compuestos fenólicos a partir de biomasa
EP3184505A1 (fr) 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé de préparation de composés phénoliques à l'aide d'un catalyseur
US20220202774A1 (en) * 2019-04-09 2022-06-30 Neurobit Science Co., Ltd. Pharmaceutical composition for prevention or treatment of spinal cord injury or spinal stenosis
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN111454150B (zh) * 2019-12-25 2023-03-28 南京工业大学 一种(s)-2-芳基丙酸酯类化合物的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (fr) 1998-09-14 2002-09-04 Ono Pharmaceutical Co DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003207900A1 (en) 2002-03-18 2003-09-29 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
WO2003086371A2 (fr) 2002-04-12 2003-10-23 Pfizer Japan Inc. Utilisation de ligands du recepteur ep4 dans le traitement de maladies impliquant il-6
CA2483555A1 (fr) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
WO2004037813A1 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
CA2514220C (fr) 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Antagonistes aux recepteurs ep4
EP1663979B1 (fr) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
WO2005105732A1 (fr) 2004-05-04 2005-11-10 Pfizer Japan Inc. Composes methylaryl- ou heteroarylamides substitues
ATE435198T1 (de) 2004-05-04 2009-07-15 Raqualia Pharma Inc Orthosubstituierte aryl- oder heteroarylamidverbindungen
WO2005116010A1 (fr) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof
CA2608214C (fr) * 2005-05-19 2013-08-20 Merck Frosst Canada Ltd. Derives de quinoleine a titre d'antagonistes de ep4

Also Published As

Publication number Publication date
WO2008071736A1 (fr) 2008-06-19
AU2007331471B2 (en) 2013-01-10
NO20092314L (no) 2009-08-31
EA015931B1 (ru) 2011-12-30
CR10849A (es) 2009-08-12
DOP2009000124A (es) 2010-03-31
JP5069752B2 (ja) 2012-11-07
AU2007331471C1 (en) 2013-07-25
US20100022650A1 (en) 2010-01-28
SG177203A1 (en) 2012-01-30
EP2101751A1 (fr) 2009-09-23
US20130261185A1 (en) 2013-10-03
NZ577109A (en) 2011-12-22
AR064361A1 (es) 2009-04-01
IL198931A0 (en) 2010-02-17
US20080167377A1 (en) 2008-07-10
MX2009006474A (es) 2009-06-26
CL2007003640A1 (es) 2008-07-11
US8314147B2 (en) 2012-11-20
JP2010513242A (ja) 2010-04-30
KR20090089868A (ko) 2009-08-24
PE20081579A1 (es) 2009-01-01
AU2007331471A1 (en) 2008-06-19
BRPI0720254A2 (pt) 2014-01-07
CA2672631A1 (fr) 2008-06-19
TW200848014A (en) 2008-12-16
EA200970585A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MA38325A2 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA31988B1 (fr) Derives d'aminopyrazole
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA32231B1 (fr) Composés organiques
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MA30284B1 (fr) Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MA31699B1 (fr) Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3
JO2937B1 (en) Tight muscles of the peptide vascular tensioner receptor
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.